Effects of naloxone and diazepam on blood glucose levels in tramadol overdose using generalized estimating equation (GEE) model; (an experimental study).


Journal

BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676

Informations de publication

Date de publication:
06 Sep 2021
Historique:
received: 04 01 2021
accepted: 24 08 2021
entrez: 7 9 2021
pubmed: 8 9 2021
medline: 18 1 2022
Statut: epublish

Résumé

Tramadol is a synthetic opioid and poisoning is increasing around the world day by day. Various treatments are applied for tramadol poisoning. Due to the unknown effects of tramadol poisoning and some of its treatments on blood glucose levels, this study was conducted to investigate the overdose of tramadol and its common treatments (naloxone, diazepam), and their combination on blood glucose levels in male rats. This study was conducted in 45 male Wistar rats. The animals were randomly divided into five groups of 9. They received a 75 mg/kg dose of tramadol alone with naloxone, diazepam, and a combination of both of these two drugs. On the last day, animals' tail vein blood glucose levels (BGL) were measured using a glucometer at different times, including before the tramadol injection (baseline) and 1 hour, 3 hours, and 6 hours after wards. The rats were anesthetized and sacrificed 24 h after the last injection. Blood samples were then taken, and the serum obtained was used to verify the fasting glucose concentration. Data were analyzed using SPSS software at a significance level of 0.05 using a one-way analysis of variance (ANOVA) and a generalized estimating equation (GEE). According to the GEE model results, the diazepam-tramadol and naloxone-diazepam-tramadol groups showed blood glucose levels five units higher than the tramadol group (p < 0.05). The diazepam-tramadol group had significantly higher blood glucose levels than the naloxone-tramadol group (p < 0.05). The mean blood glucose levels before the intervention, 3 hours and 6 hours after the injection of tramadol did not differ between the groups, but the blood glucose levels 1 hour after the injection of tramadol in the group of naloxone-tramadol were significantly lower than in the control group (p < 0.05). Blood glucose levels did not differ between the groups 24 h after injection of tramadol. The results of the present study showed tramadol overdose does not affect blood glucose levels. The diazepam-tramadol combination and the diazepam-naloxone-tramadol combination caused an increase in blood glucose levels.

Sections du résumé

BACKGROUND BACKGROUND
Tramadol is a synthetic opioid and poisoning is increasing around the world day by day. Various treatments are applied for tramadol poisoning. Due to the unknown effects of tramadol poisoning and some of its treatments on blood glucose levels, this study was conducted to investigate the overdose of tramadol and its common treatments (naloxone, diazepam), and their combination on blood glucose levels in male rats.
METHODS METHODS
This study was conducted in 45 male Wistar rats. The animals were randomly divided into five groups of 9. They received a 75 mg/kg dose of tramadol alone with naloxone, diazepam, and a combination of both of these two drugs. On the last day, animals' tail vein blood glucose levels (BGL) were measured using a glucometer at different times, including before the tramadol injection (baseline) and 1 hour, 3 hours, and 6 hours after wards. The rats were anesthetized and sacrificed 24 h after the last injection. Blood samples were then taken, and the serum obtained was used to verify the fasting glucose concentration. Data were analyzed using SPSS software at a significance level of 0.05 using a one-way analysis of variance (ANOVA) and a generalized estimating equation (GEE).
RESULTS RESULTS
According to the GEE model results, the diazepam-tramadol and naloxone-diazepam-tramadol groups showed blood glucose levels five units higher than the tramadol group (p < 0.05). The diazepam-tramadol group had significantly higher blood glucose levels than the naloxone-tramadol group (p < 0.05). The mean blood glucose levels before the intervention, 3 hours and 6 hours after the injection of tramadol did not differ between the groups, but the blood glucose levels 1 hour after the injection of tramadol in the group of naloxone-tramadol were significantly lower than in the control group (p < 0.05). Blood glucose levels did not differ between the groups 24 h after injection of tramadol.
CONCLUSION CONCLUSIONS
The results of the present study showed tramadol overdose does not affect blood glucose levels. The diazepam-tramadol combination and the diazepam-naloxone-tramadol combination caused an increase in blood glucose levels.

Identifiants

pubmed: 34488743
doi: 10.1186/s12902-021-00847-x
pii: 10.1186/s12902-021-00847-x
pmc: PMC8422785
doi:

Substances chimiques

Analgesics, Opioid 0
Blood Glucose 0
Hypnotics and Sedatives 0
Narcotic Antagonists 0
Naloxone 36B82AMQ7N
Tramadol 39J1LGJ30J
Diazepam Q3JTX2Q7TU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

180

Informations de copyright

© 2021. The Author(s).

Références

Presse Med. 2006 Dec;35(12 Pt 1):1842-4
pubmed: 17159739
Toxicol Lett. 2005 Jul 4;157(3):221-32
pubmed: 15917147
Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):74-82
pubmed: 1100541
Basic Clin Pharmacol Toxicol. 2012 Aug;111(2):133-6
pubmed: 22364547
Clin Toxicol (Phila). 2018 Aug;56(8):737-743
pubmed: 29148295
Diabetes. 1984 Jul;33(7):619-21
pubmed: 6734943
Anesth Prog. 2004;51(1):14-8
pubmed: 15106685
Pak J Pharm Sci. 2015 Nov;28(6):1959-63
pubmed: 26639492
Mol Cell Endocrinol. 1994 Jul;103(1-2):157-63
pubmed: 7958392
Diabetes. 2001 Dec;50(12):2815-21
pubmed: 11723065
Forensic Sci Int. 2008 Feb 25;175(1):79-82
pubmed: 17875377
Expert Rev Clin Pharmacol. 2020 May;13(5):531-543
pubmed: 32295441
Life Sci. 1989;45(20):1931-6
pubmed: 2689822
Ann Pharmacother. 2005 Jun;39(6):1039-44
pubmed: 15870139
Int J Prev Med. 2014 Mar;5(3):302-7
pubmed: 24829714
Therapie. 2017 Dec;72(6):615-624
pubmed: 28755832
Life Sci. 1998;63(14):1221-6
pubmed: 9771911
Emerg Med J. 2010 Dec;27(12):928-30
pubmed: 20378740
Life Sci. 2007 Apr 24;80(20):1832-8
pubmed: 17397876
Endocr Pract. 2012 Nov-Dec;18(6):e151-2
pubmed: 22982791
BMJ Case Rep. 2010 Aug 06;2010:
pubmed: 22767676
Biomed Pharmacother. 2021 Jan;133:111031
pubmed: 33249277
Neurosci Lett. 1994 Feb 28;168(1-2):243-6
pubmed: 8028785
Crit Rev Toxicol. 2019 Sep;49(8):710-723
pubmed: 31914355
Saudi J Med Med Sci. 2016 Jan-Apr;4(1):35-37
pubmed: 30787694
Toxicol Appl Pharmacol. 2016 Nov 1;310:108-119
pubmed: 27641627
Am J Emerg Med. 2009 Sep;27(7):903.e5-7
pubmed: 19683139
Eur J Clin Pharmacol. 2011 Aug;67(8):855-8
pubmed: 21691803
Hum Exp Toxicol. 2008 Mar;27(3):201-5
pubmed: 18650251
Life Sci. 2000 Feb 18;66(13):1213-21
pubmed: 10737416
Malays J Med Sci. 2017 Oct;24(5):101-105
pubmed: 29386977
Am J Emerg Med. 2013 Jan;31(1):26-31
pubmed: 22809771
Ann Emerg Med. 2012 Jun;59(6):545-7
pubmed: 21924518
J Clin Invest. 1967 Jan;46(1):86-94
pubmed: 6018752
Diabetologia. 2002 Feb;45(2):242-52
pubmed: 11935156
Indian J Exp Biol. 2001 Apr;39(4):378-80
pubmed: 11491585
JAMA Intern Med. 2015 Feb;175(2):194-5
pubmed: 25486516
Expert Opin Drug Metab Toxicol. 2020 Jul;16(7):627-640
pubmed: 32476523
Epilepsy Res. 1993 Sep;16(1):51-4
pubmed: 8243439
J Clin Endocrinol Metab. 1980 Feb;50(2):251-7
pubmed: 6243662

Auteurs

Samaneh Nakhaee (S)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran.

Khadijeh Farrokhfall (K)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran.

Ebrahim Miri-Moghaddam (E)

Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Masoumeh Askari (M)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran.

Alireza Amirabadizadeh (A)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran.

Mohsen Foadoddini (M)

Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Omid Mehrpour (O)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran. omid.mehrpour@yahoo.com.au.
Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA. omid.mehrpour@yahoo.com.au.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH